20 21 RB-E2F transcriptional control plays a key role in regulating the timing of cell cycle 22 progression from G1 to S-phase in response to growth factor stimulation. Despite this 23 role, it is genetically dispensable for cell cycle exit in primary fibroblasts in response to 24 growth arrest signals. Mice engineered to be defective for RB-E2F transcriptional 25 control at cell cycle genes were also found to live a full lifespan with no susceptibility to 26 cancer. Based on this background we sought to probe the vulnerabilities of RB-E2F 27 transcriptional control defects found in Rb1 R461E,K542E mutant mice (Rb1 G ) through genetic 28 crosses with other mouse strains. We generated Rb1 G/G mice in combination with Trp53 29 and Cdkn1a deficiencies, as well as in combination with Kras G12D . The Rb1 G mutation 30 enhanced Trp53 cancer susceptibility, but had no effect in combination with Cdkn1a 31 deficiency or Kras G12D . Collectively, this study indicates that compromised RB-E2F 32 transcriptional control is not uniformly cancer enabling, but rather has potent oncogenic 33 effects when combined with specific vulnerabilities.
140 Results 141 142 Defective RB-E2F transcriptional control results in accelerated cell cycle entry. 143 We previously reported the generation of a mouse strain in which the endogenous 144 Rb1 gene was modified to express a synthetic mutant RB protein that is designed to 145 disrupt RB's ability to interact with the activation domain of E2F transcription factors 146 (16, 17 
183
We aged cohorts of control Trp53 -/mutant mice and Rb1 G/G ; Trp53 -/animals to 184 determine their susceptibility to cancer. This revealed that Rb1 G/G ; Trp53 -/mutant mice 185 experienced a significantly shorter disease free survival compared to Trp53 -/controls 186 ( Fig. 2A ). Trp53 -/knock out mice are known to succumb primarily to thymic 187 lymphomas and sarcomas (26), and we observed both in our control cohort of Trp53 -/ -One shortcoming of investigating cancer predisposition in mutant mice that 235 uniformly possess loss of function mutations is that a critical initiating event may be 236 missing. For this reason we also crossed Rb1 G/G mutants with mice expressing an 237 oncogenic form of Kras in order to stimulate proliferation and provide aberrant survival 238 signals. To accomplish this we utilized the latent LSL-KrasG12D mutant that has 239 previously been reported (23). In order to be consistent with previous experiments we 240 utilized the UBC9-Cre-ERT2 transgene and mild tamoxifen delivery so that the Kras G12D 241 allele is expressed in some cells in potentially many tissues.
242
We generated cohorts of LSL-Kras G12D ; UBC-Cre-ERT2 and Rb1 G/G ; LSL- 
